Navigation Links
Newer Blood Pressure Drug Better for Some Heart Patients, Diabetics
Date:8/31/2008

Study found telmisartan offered slight benefit for those unable to take ACE inhibitors

SUNDAY, Aug. 31 (HealthDay News) -- A new study offers a possible alternative to heart patients and diabetics who need to keep their blood pressure under control but who cannot tolerate the standard treatment of ACE inhibitors.

Reporting at the European Society of Cardiology in Munich on Sunday, Canadian researchers said they found that the angiogenesis-receptor blocker (ARB) known as telmisartan worked well for the 20 percent of patients with vascular disease and high-risk diabetes who can't take ACE inhibitors. The study was released in the Aug. 31 online issue of The Lancet to coincide with the meeting presentation.

In the randomized, controlled trial, almost 6,000 patients with vascular disease or high-risk diabetes took either telmisartan or a placebo, and were followed for almost five years. Rates of death, heart attack, stroke or hospitalization for heart failure were tracked as primary outcome measures during the study period.

Mean blood pressure was lower in the telmisartan group by 4.0/2.2 mm/Hg, and there was a relative risk reduction of 13.3 percent for those taking telmisartan. Fewer patients on the medication wound up in the hospital for cardiovascular problems (30.3 percent), compared to those on placebo (33 percent).

"These data suggest that telmisartan confers a modest benefit when added to other proven therapies," the researchers wrote in a news release from the journal. "In view of the drug's tolerability and effect on cardiovascular endpoints, telmisartan could be regarded as a potential treatment for patients with vascular disease or high-risk diabetes, if they are unable to tolerate an ACE inhibitor."

However, an accompanying commentary from U.S. experts dampened the significance of the finding.

"ARBs that have been studied in coronary disease are safe, but possibly less effective alternatives in patients with intolerance to ACE inhibitors. Although data are too limited to reach definitive conclusions, the clinical effect of ARBs seems less robust than that of ACE inhibitors," wrote Dr. Toni Ripley and Dr. Donald Harrison, from the University of Oklahoma College of Pharmacy.

And U.S. researchers reported on Wednesday that telmisartan does not lower the rate of stroke, cardiovascular events or diabetes better than a placebo in patients who have had a stroke.

More information

For more on ARBs, go to U.S. Food and Drug Administration.



-- HealthDay staff



SOURCE: The Lancet, news release, Aug. 31, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Newer Blood Pressure Drug No Better Than Placebo in Preventing Stroke
2. Newer Prostate Cancer Treatment Similar to Traditional Surgery
3. Newer Rheumatoid Arthritis Drugs Lower Production of B Cells
4. Newer Sedative Might Help Patients on Ventilators
5. Newer Anticlotting Drug Safe, Effective for Heart Surgeries
6. Newer radiation treatment easier for some throat cancer patients
7. Newer Antibiotic Speeds TB Healing
8. Newer antidepressants led to less, not more, teen suicides
9. Most Patients With Irregular Heartbeat Take Inadequate Blood Thinner Dose
10. Finding May Allow Some Women to Stop Blood Thinners
11. For Rare Blood Disorder, Pumping Iron Is the Cure
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Newer Blood Pressure Drug Better for Some Heart Patients, Diabetics
(Date:5/5/2016)... ... May 05, 2016 , ... MAP Health ... announced today that Enlightened Solutions has joined the Premier Outcomes-Driven Provider Network. By ... continuum for their patients being treated for substance use. , Enlightened Solutions was ...
(Date:5/5/2016)... ... May 05, 2016 , ... Liposuction specialist Marcia V. ... in St. Louis, Missouri at the Marriot St. Louis Airport Hotel. This year’s conference ... to address the conference about her unique specialization in treating Lipedema. Dr. Byrd is ...
(Date:5/5/2016)... ... ... Nepenthe Laboratory Services (NLS), a premier drug monitoring and toxicology laboratory, held ... donations for Food for Lane County, and to help support awareness for the upcoming ... assembly was to create an exciting atmosphere for the kids at Riverbend to aspire ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... Augusta Public ... its school nurses. This partnership will enable school health offices to streamline and bolster ... Butler County, Kansas, just east of Wichita. Augusta public schools serve 2,300 students among ...
(Date:5/5/2016)... ... May 05, 2016 , ... In ... health, today GrassrootsHealth, a public health promotion and research organization, declared May as ... technology-driven society, and other shifts in cultural behavior over the past several decades, ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... 2016 Research and ... Thalassaemia Market and Competitive Landscape Highlights - ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ... Competitive Landscape Highlights - 2016, provides comprehensive ... Thalassaemia market valuations and forecast, Thalassaemia products ...
(Date:5/4/2016)... time for an upgrade. There are many medical recorders on the market but none ... DVMAXX HD  offers unparalleled connectivity and functionality.  Ampronix  is a renowned authorized reseller ... innovative technology.  Photo - http://photos.prnewswire.com/prnh/20160503/363416 ... ... ...
(Date:5/4/2016)... May 4, 2016 In ... a series of free workshops across ... requirements for Good Distribution Practices (GDP). Good ... ensures that products are consistently stored, transported and handled ... (MA) or product specification. Only a few years ago, ...
Breaking Medicine Technology: